Aarti Drugs (NSE:AARTIDRUGS, BOM:524348) has restored production for a "particular product" at its T-150 unit at Tarapur in Maharashtra, India, according to a filing to the stock exchanges on Saturday.
In August, the company received 'Conditional Restart Directions' for manufacturing activity from the Maharashtra Pollution Control Board, after which the company restored the manufacturing process in compliance with the Directorate of Industrial Safety and Health (DISH) recommendations.
The company said the stoppage of manufacturing of the product has no material impact on the financials and operations of the business.